TNF Inhibitors in Psoriasis: A Review.
Semin Cutan Med Surg
; 34(2 Suppl): S37-9, 2015 Mar.
Article
en En
| MEDLINE
| ID: mdl-26625254
ABSTRACT
Adalimumab, etanercept, and infliximab are tumor necrosis factor (TNF) inhibitors that are currently approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis. The availability of these biologic agents established a new benchmark in the treatment of psoriasis that requires systemic therapy to control psoriasis signs and symptoms. Although a number of other biologic agents and small molecules have been approved recently, TNF inhibitors remain a cornerstone of psoriasis therapy. Semin Cutan Med Surg 34(supp2)S37-S39 © 2015 published by Frontline Medical Communications.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Idioma:
En
Revista:
Semin Cutan Med Surg
Asunto de la revista:
DERMATOLOGIA
Año:
2015
Tipo del documento:
Article